EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation Meeting Abstract
| Authors: | Sharma, P.; Farooki, A.; Fasching, P. A.; Loi, S.; Peterson, K.; Prat, A.; Tripathy, D.; Xu, B.; Yardley, D. A.; Mills, D.; Klauss, G.; Wong, C.; André, F. |
| Abstract Title: | EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S387 |
| End Page: | S388 |
| Language: | English |
| ACCESSION: | WOS:000573469100349 |
| DOI: | 10.1016/j.annonc.2020.08.451 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 349TiP -- Source: Wos |
